Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.

The US FDA has approved ocrelizumab (Ocrevus, Genentech) intravenous infusion for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS) who weigh at least 55 lbs (25 kg), ...

Rakan fought his cancer, a rare form of pediatric kidney cancer known as diffused anaplastic Wilms’s tumor, with a ferocity ...

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in ...

MS is three times more common in females than in males. Females are more likely to have relapsing forms of MS, with an earlier onset than men. Menstrual changes and more intense fatigue and pain are ...

A routine hospital scan quickly became anything but routine. Doctors discovered Ms Ferreira’s waters had broken prematurely ...

Broward Children's Center (BCC) – a nonprofit organization dedicated to serving infants, children and young adults who are ...

Children were more likely to undergo an evaluation if they had public insurance, had a higher BMI, had English as a primary ...

Autolus Therapeutics PLC (AUTL) reports significant revenue growth and operational milestones, while navigating financial losses and market expansion hurdles.

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit The FDA has approved Ocrevus for treating relapsing-remitting multiple sclerosis among children 10 ...

Those injured were taken to area hospitals, Miami-Dade Fire Rescue said. Emergency crews responded Saturday near the Haulover ...

PHILADELPHIA, May 13, 2026--iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine ...